WCDPQ Plans South American Expansion in 2027, Including 30 New Positions 
Hong Kong International Optical Fair opens in November 
Chervon Appoints Stephen Sarnocinski to President – End User Research, Sales and Service – OPE Commercial Landscaping Market Global 
PFN and Tenstorrent Selected for NEDO Project on “xPU Design and Development Incorporating Photonics Electronics Integration Technology” 
GTJAI Assists in the Successful Issuance of Central Asia’s First Sovereign Wealth Fund Offshore RMB Bond Outpace Bio, a Leader in Protein Design & Cell Engineering, Adds Bahija Jallal to Board of Directors
Jallal, an internationally recognized biopharma leader, oversaw historic approval of the world’s first TCR therapy…
Outpace Bio, a Leader in Protein Design & Cell Engineering, Adds Bahija Jallal to Board of Directors
Jallal, an internationally recognized biopharma leader, oversaw historic approval of the world’s first TCR therapy…
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’ Mushroom Microdose Supplements VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) —…
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’ Mushroom Microdose Supplements VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) —…
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development…
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development…
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
– Company ended the year with $50.6 million in cash, expected to fund operations through…
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
– Company ended the year with $50.6 million in cash, expected to fund operations through…
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2…
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2…
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the…
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the…
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA),…
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA),…
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK,…
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK,…